Foretinib (GSK1363089)

Cat. No.: OB0225WX-2394

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Foretinib (GSK1363089) is an ATP-competitive antagonist of HGFR and VEGFR, specifically targeting c-Met and KDR with IC50 values of 0.4 nM and 0.9 nM, respectively.

Synonym: EXEL-2880, XL-880, GSK089; 849217-64-7; Foretinib; XL880; GSK1363089; GSK 1363089; XL 880; EXEL 2880; GSK-1363089; GSK-089; GSK1363089G; N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; 81FH7VK1C4; GSK-1363089G; 937176-80-2; 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 88Z; n-(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-(3-Fluoro-4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinolin-4-Yl]oxy}phenyl)-N'-(4-Fluorophenyl)cyclopropane-1,1-Dicarboxamide; N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; XL 880; N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl]oxy)phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; MFCD16038048

CAS No.: 849217-64-7

Compound CID: 42642645

Formula: C₃₄H₃₄F₂N₄O₆

Formula Weight: 632.65

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Foretinib (GSK1363089) is applied in advanced cancer research as a dual MET and VEGFR2 inhibitor to investigate the disruption of hepatocyte growth factor-mediated signaling and tumor vascularization.